FDA approves Portrazza(TM) (necitumumab) for specific type of lung cancer
Eli Lilly announced the FDA has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with metastatic squamous NSCLC. November 24, 2015